CONCLUSIONS: The GG genotype of MDM2 SNP309 is associated with an earlier onset of head and neck squamous cell carcinoma (HNSCC) in the Japanese population. SNP309 may be a key factor in the tumorigenesis of HNSCC as well as other hereditary or sporadic tumors. OBJECTIVE: This study was designed to evaluate the association between the single nucleotide polymorphism (SNP) 309 in the MDM2 gene with HNSCC. An MDM2 protein down-regulates the p53 pathway. Recently, an important SNP was discovered in the MDM2 promoter region, which could affect the tumorigenesis of HNSCC by attenuation of the p53 pathway. PATIENTS AND METHODS: Patients with 103 HNSCCs were genotyped using direct sequencing and real-time PCR. The relationship between the SNP309 genotypes and the clinicopathological features was statistically analyzed. RESULTS: The number of patients genotyped to TT, TG, and GG was 29 (28%), 46 (44.7%), and 28 (27.2%), respectively. The average age at tumor onset was 65.6 years for TT, 62.9 years for TG, and 56.7 years for GG. The patients with the GG genotype had a significantly earlier tumor onset in comparison to those with the TT genotype (p=0.032).
CONCLUSIONS: The GG genotype of MDM2SNP309 is associated with an earlier onset of head and neck squamous cell carcinoma (HNSCC) in the Japanese population. SNP309 may be a key factor in the tumorigenesis of HNSCC as well as other hereditary or sporadic tumors. OBJECTIVE: This study was designed to evaluate the association between the single nucleotide polymorphism (SNP) 309 in the MDM2 gene with HNSCC. An MDM2 protein down-regulates the p53 pathway. Recently, an important SNP was discovered in the MDM2 promoter region, which could affect the tumorigenesis of HNSCC by attenuation of the p53 pathway. PATIENTS AND METHODS: Patients with 103 HNSCCs were genotyped using direct sequencing and real-time PCR. The relationship between the SNP309 genotypes and the clinicopathological features was statistically analyzed. RESULTS: The number of patients genotyped to TT, TG, and GG was 29 (28%), 46 (44.7%), and 28 (27.2%), respectively. The average age at tumor onset was 65.6 years for TT, 62.9 years for TG, and 56.7 years for GG. The patients with the GG genotype had a significantly earlier tumor onset in comparison to those with the TT genotype (p=0.032).
Authors: Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond Journal: Cold Spring Harb Perspect Biol Date: 2009-12-09 Impact factor: 10.005
Authors: Geoffrey Childs; Melissa Fazzari; Gloria Kung; Nicole Kawachi; Margaret Brandwein-Gensler; Michael McLemore; Quan Chen; Robert D Burk; Richard V Smith; Michael B Prystowsky; Thomas J Belbin; Nicolas F Schlecht Journal: Am J Pathol Date: 2009-01-29 Impact factor: 4.307
Authors: Gurinder Singh Atwal; Tomas Kirchhoff; Elisabeth E Bond; Marco Montagna; Marco Monagna; Chiara Menin; Roberta Bertorelle; Maria Chiara Scaini; Frank Bartel; Anja Böhnke; Christina Pempe; Elise Gradhand; Steffen Hauptmann; Kenneth Offit; Arnold J Levine; Gareth L Bond Journal: Proc Natl Acad Sci U S A Date: 2009-06-04 Impact factor: 11.205
Authors: Anja Rogler; Sabine Hoja; Eileen Socher; Elke Nolte; Sven Wach; Wolf Wieland; Ferdinand Hofstädter; Peter J Goebell; Bernd Wullich; Arndt Hartmann; Robert Stoehr Journal: Int J Clin Exp Pathol Date: 2013-09-15